PPARs and Liver Disease
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai City, Miyagi 980-8574, Japan
2Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai City, Miyagi 980-8574, Japan
3Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
4Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 0165, USA
PPARs and Liver Disease
Description
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and have been implicated in a variety of pathologic process. PPARs require heterodimerization with receptor X for retinoids (RXR) to have function. PPARα/β/δ/γ, with RXR, are important nuclear receptors expressed in the liver and contribute to the control of glucose and lipid metabolism, cell proliferation and inflammation, and so forth. PPARs became considered as the target molecules of human metabolic disease such as nonalcoholic fatty liver disease (NAFLD) including NASH, since PPAR activation has been associated with anti-inflammatory and antifibrotic functions in the liver. Among the liver disease, PPARs could contribute to the pathogenesis of chronic hepatitis C (CHC), chronic hepatitis B (CHB), and hepatocellular carcinoma (HCC) in addition to NAFLD. For example, HCV infection is characterized by disturbance of glucose and lipid metabolism leading to fat accumulation in hepatocytes. Therefore, the varieties of liver disease are also related to the PPARs. In this special issue, we should collect various kinds of research and review articles regarding PPARs and liver diseases to understand the detailed contribution of PPARs in liver diseases. Potential topics include, but are not limited to:
- PPARs and NAFLD (control of lipid and lipoprotein metabolism)
- PPARs and alcohol-induced liver diseases (Anti-inflammatory immunomodulatory properties)
- PPARs and hepatitis C virus persistent infection
- PPARs on viral transcription and replication during hepatitis B virus persistent infection
- Modulation of PPARs expression during chronic hepatitis virus infection
- PPARs and Hepatocellular carcinoma
- PPARs and liver immunology
- PPARs and hepatic glucose metabolism
- PPARs and recent topic of liver diseases
- Treatment of liver diseases using PPAR ligands
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ppar/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: